Invicro, LLC services

Invicro has a vast range of tools that help accelerate your drug discovery and development process. Our technology platforms support key decision-making in: Early discovery and screening. Candidate selection. First-in-human translation and early development. Late stage, multi-center determination of efficacy.

Invicro’s clinical capabilities span from early phase, first-in-human through late phase and post-approval studies. We focus on studies containing imaging and pathology-based endpoints requiring robust, independent assessments to ascertain drug efficacy. Our imaging core lab and CAP/CLIA lab-based pathology services solutions support various therapeutic areas including oncology, immuno-oncology, neurology (CNS), cardiovascular, musculoskeletal and gastrointestinal. Our experience comes from years of successful execution of Phase II-IV studies across the development spectrum led by a leadership team with an average of 25 years of industry experience.

Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.^1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is expressed in high levels in prostate cancer cells. Due to its location on the cell surface, PSMA is a popular target for imaging to identify the presence of prostate cancer and to deliver drugs directly to the cancerous cells³. A PSMA-PET scan is a powerful molecular imaging technique that can accurately localize prostate cancer and assess the level of a tumor’s PSMA expression. There are currently two USFDA and one EMA-approved PSMA-PET agents that are widely used in both clinic and trials. In early 2022, the USFDA approved the first targeted radioligand therapy, 177Lu-PSMA-61, for use in men with metastatic prostate cancer whose tumors overexpress the PSMA protein⁴.

Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells, while limiting damage to normal and healthy tissue. Streamlined development, evaluation and clinical translation of radiopharmaceuticals requires a partner that has extensive scientific, regulatory and operational expertise. Working with a CRO that provides a complete solution ensures data is delivered in a timely manner to make a go/no-go decision on your imaging or therapeutic candidates.

Our diverse team of experts have experience in instrument engineering, signal processing, and pharmaceutical R&D, collectively resulting in a long history designing and executing imaging and pathology studies. Our scientists have performed hundreds of  studies across multiple therapeutic research areas, including oncology, neuroscience, inflammation, cardiovascular, metabolic, and musculoskeletal, and our experience runs the gamut of applications. We understand the physiological and biochemical mechanisms that affect imaging—targets, models, kinetics, and more. This vast hands-on experience allows us to understand drug behavior and translate knowledge to provide effective studies and useful data.

Invicro is an medical imaging CRO with over 210 scientists, 60+ PhD’s and MD’s and 2100+ qualified imaging centers across the globe. We possess scientific and regulatory expertise, project management scale and operational excellence to manage all the clinical trial imaging components of your Phase I-IV clinical trials across the therapeutic spectrum and spanning imaging modalities.

Invicro’s Advanced Pathology Services (APS) team provides end-to-end solutions to support translational and clinical research by providing a combination of routine and unique tissue testing services. As part of the REALM IDx, Inc. group, our pathology service laboratories support projects spanning preclinical biomarker discovery research to clinical trials and development of companion diagnostics (CDx) products. Our scientific, operational and regulatory expertise enables us to deliver insights needed to take lead drug candidates to the next level.

Invicro’s medical image analysis team develops robust algorithms and pipelines to solve complex image science problems. Our team of over fifty medical image processing scientists, including more than twenty PhDs, is responsible for extracting scientific quantitative data in support of Invicro’s studies from discovery research through late-phase clinical trials. The medical image analysis team blends cutting edge image science with proven image engineering capabilities to continually create novel algorithms and quantitative image analysis pipelines while also developing those methods into robust, efficient automated tools. Machine learning and deep learning are two powerful tools routinely used to drive these solutions. These methods are coupled with Invicro’s deep scientific domain knowledge to produce unique, custom solutions to a variety of tasks, spanning therapeutic area and modality.